Ascendiant Capital Starts Aastrom Biosciences (ASTM) at Strong Buy; Leading Pure Play in Regenerative Medicine
Tweet Send to a FriendGet Alerts ASTM Hot Sheet
Price: $0.59 +3.51%
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Trade ASTM Now!
Ascendiant Capital initiates coverage on Aastrom Biosciences (NASDAQ: ASTM) with a Strong Buy. PT $4.25.
Analyst, Keay Nakae, said, "We believe that Aastrom is one of the best positioned, pure play regenerative medicine companies. The Company’s key product, ixmyelocel-T, is an autologous, bone marrow-derived cell therapy product being developed for the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Aastrom has begun patient enrollment in a Phase 3 study for CLI, while DCM is in Phase 2."
For an analyst ratings summary and ratings history on Aastrom Biosciences click here. For more ratings news on Aastrom Biosciences click here.
Shares of Aastrom Biosciences closed at $2.32 yesterday, with a 52 week range of $1.75-$3.47.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Keay Nakae, said, "We believe that Aastrom is one of the best positioned, pure play regenerative medicine companies. The Company’s key product, ixmyelocel-T, is an autologous, bone marrow-derived cell therapy product being developed for the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Aastrom has begun patient enrollment in a Phase 3 study for CLI, while DCM is in Phase 2."
For an analyst ratings summary and ratings history on Aastrom Biosciences click here. For more ratings news on Aastrom Biosciences click here.
Shares of Aastrom Biosciences closed at $2.32 yesterday, with a 52 week range of $1.75-$3.47.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
- JPMorgan Starts Taylor Morrison Home (TMHC) at Overweight
- Piper Jaffray Starts Mattel Inc. (MAT) at Overweight
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
